Melanocortin-1 receptor (MC1R) is a molecular target for melanoma imaging and therapy because of its overexpression on rodent and human melanoma cells. Here, we evaluated the MC1R targeting and specificity of 68 Ga-DOTA-GGNle-CycMSH hex and Cy5.5-GGNle-CycMSH hex using murine and human melanoma cells, and murine and xenografted tumors.
INTRODUCTION
Malignant melanoma is the most lethal form of skin cancer with an increasing rate of incidence. Although malignant melanoma makes up less than 5% of skin cancer cases, it accounts for 75% of all skin cancer deaths (1) . About 76,380 new cases and 10,130 fatalities occurred in the United States in 2016 (1) . The high mortality rate of melanoma is due to the extreme aggressiveness associated with metastatic melanoma. Unfortunately, the success of traditional treatments, such as dacarbazine chemotherapy, interleukin-2, and interferon- immunotherapy, is limited for metastatic melanoma, with a traditional median overall survival of 6 to 9 months (2, 3) .
Over the past several years, new molecular approaches including targeting BRAF-V600E mutation, cytotoxic T lymphocyte antigen 4 (CTLA-4), and programmed death-1 receptor (PD-1) have shown promising results in treating metastatic melanoma (4) (5) (6) (7) (8) . For instance, the treatments of vemurafenib (BRAF inhibitor), ipilimumab (targeting CTLA-4), and nivolumab (PD-1 inhibitor) have improved median overall survival by months in patients with metastatic melanoma (4) (5) (6) (7) (8) . However, long-term survival of patients with metastatic melanoma remains at <10%. Therefore, it is highly desirable to develop new treatments for metastatic melanoma.
Melanocortin-1 receptor (MC1R) is a G protein-coupled receptor overexpressed on both rodent and human melanoma cells (9) (10) (11) (12) (13) (14) (15) (16) . Greater than 80% of melanotic and amelanotic human metastatic melanomas overexpresses MC1R (9) , making it an attractive molecular target for developing receptor-targeting radiopharmaceuticals for melanoma imaging and therapy. Meanwhile, -melanocyte-stimulating hormone (-MSH) and its analogs can bind to MC1Rs with nanomolar binding affinities, suggesting the feasibility of using -MSH peptides to deliver diagnostic and therapeutic radionuclides to melanoma cells via peptide-MC1R binding for melanoma imaging and therapy (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) . Upon MC1R binding, -MSH peptides can be internalized into melanoma cells (28, 29) .
Over several years, we have developed radiolabeled lactam-cyclized -MSH peptides for melanoma targeting, built upon the construct of DOTA-GGNle-CycMSH hex (1,4,7,10-tetraazacyclononane-1,4,7,10-tetraacetic acid-Gly-Gly-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-CONH 2 ) (24, 25, 27, (30) (31) (32) (33) (34) . DOTA-GGNle-CycMSH hex was readily radiolabeled with 111 In and 67 Ga for melanoma imaging using single photon emission computed tomography (SPECT) (24, 30) and 177 Lu for potential targeted radionuclide therapy of melanoma (32) . High B16/F1 melanoma uptake (25.53 ± 2.22% ID/g), fast urinary clearance (84.91 ± 2.81% ID), and high tumor/normal organ uptake ratios at 2 hours after injection of 67 Ga-DOTA-GGNle-CycMSH hex (30) demonstrated its potential as an imaging probe for melanoma imaging using SPECT. High B16/F1 melanoma uptake (21.63 ± 6.27% ID/g) at 2 hours after injection and prolonged melanoma retention (8.24 ± 1.51% ID/g) at 24 hours after injection of 177 Lu-DOTA-GGNleCycMSH hex (32) highlighted its potential for targeted radionuclide therapy of melanoma.
Building upon the promising results of 67 Ga-DOTA-GGNleCycMSH hex and 177 Lu-DOTA-GGNle-CycMSH hex , we developed positron emission tomography (PET) imaging probes for melanoma, taking advantage of PET's high sensitivity and fast acquisition features. The combination of our MC1R-targeting peptide (DOTAGGNle-CycMSH hex ) with PET may potentially offer a highly sensitive molecular approach to select patients with MC1R-positive melanoma for targeted radionuclide therapy. Ga generator to be about 6 to 12 months based on elution schedules. As such, the 68 Ge/ 68 Ga generator is affordable and offers flexibility to the preparation of 68 Ga radiopharmaceuticals.
Although PET imaging using the MC1R-targeting peptide ( 68 Ga-DOTA-GGNle-CycMSH hex ) may facilitate the accurate imaging of malignant melanoma, optical fluorescence imaging is a powerful complementary tool to visualize tumor lesions that can potentially provide an opportunity to improve surgical outcome via imagingguided surgery. Therefore, we developed an MC1R-targeting fluorescence imaging probe in parallel with the MC1R-targeting PET imaging probe ( 68 Ga-DOTA-GGNle-CycMSH hex ). By replacing the DOTA chelator with fluorescence Cyanine5.5 (Cy5.5) carboxylic acid and conjugating to GGNle-CycMSH hex , we generated Cy5.5-GGNleCycMSH hex . The combination of MC1R-targeted PET and fluorescence imaging probes could potentially provide opportunities for accurate detection and imaging-guided surgical removal of melanoma lesions, as well as identification of patients with MC1R-positive melanoma for targeted radionuclide therapy.
Here, DOTA-GGNle-CycMSH hex and Cy5.5-GGNle-CycMSH hex were synthesized using 9-fluorenyl methoxycarbonyl (Fmoc) chemistry.
Their receptor binding affinities were determined on B16/F10 murine (metastatic) and M21 (low MC1R density) human melanoma cells (16, 17, 34, 35) . The MC1R expression in B16/F10 and M21 melanoma cells and tumor lesions was stained by Cy5.5-GGNle-CycMSH hex . The biodistribution and imaging properties of 68 Ga-DOTA-GGNleCycMSH hex were examined on B16/F10 flank melanoma and pulmonary metastatic melanoma models and M21 human melanoma xenografts.
68
Ga-DOTA-GGNle-CycMSH hex PET was used first in human on patients with metastatic melanoma who were considered suitable for the evaluation of experimental approaches.
RESULTS
Peptide synthesis and in vitro competitive binding assay DOTA-GGNle-CycMSH hex and Cy5.5-GGNle-CycMSH hex (Fig. 1 ) were synthesized and purified by reversed-phase high-performance liquid chromatography (RP-HPLC). After purification, DOTA-GGNleCycMSH hex and Cy5.5-GGNle-CycMSH hex displayed greater than 90% purity. The identities of DOTA-GGNle-CycMSH hex and Cy5.5-GGNle-CycMSH hex were confirmed by electrospray ionization mass spectrometry. The measured molecular weights matched with calculated molecular weights. The half-maximal inhibitory concentration (IC 50 ) values of DOTA-GGNle-CycMSH hex were 2.1 ± 0.3 nM and 1.1 ± 0.2 nM on B16/F10 and M21 melanoma cells, respectively. The IC 50 values of Cy5.5-GGNle-CycMSH hex were 7.1 ± 0.1 nM and 2.6 ± 0.3 nM on B16/F10 and M21 melanoma cells, respectively (Fig. 1) .
Radiochemistry, specific binding, and fluorescence staining

68
Ga-DOTA-GGNle-CycMSH hex was readily prepared with greater than 95% radiolabeling yield and was completely separated from excess nonlabeled peptide by RP-HPLC. The retention time of 68 Ga-DOTA-GGNle-CycMSH hex and DOTA-GGNle-CycMSH hex was 16.9 and 15.7 min, respectively.
68 Ga-DOTA-GGNle-CycMSH hex was stable in mouse serum at 37°C for 1 hour. Urine analysis revealed that 80% of the 68 Ga-DOTA-GGNle-CycMSH hex excreted renally also remained intact in urine 2 hours after injection. Ga-DOTA-GGNle-CycMSH hex uptake was blocked on B16/F10 and M21 melanoma cells, respectively (P < 0.05; Fig. 2 ). The MC1R expression in B16/F10 and M21 cells and in melanoma lesions was examined with fluorescence staining using Cy5.5-GGNle-CycMSH hex . As demonstrated in Fig. 3 , Cy5.5-GGNle-CycMSH hex showed receptor-mediated binding on B16/F10 and M21 cells, B16/ F10 and M21 flank melanoma lesions, and B16/F10 pulmonary metastatic melanoma lesions. The uptake of Cy5.5-GGNle-CycMSH hex was substantially inhibited by peptide blockade of MC1R.
Biodistribution
Tumor targeting and biodistribution properties of 68 Ga-DOTA-GGNleCycMSH hex were determined in B16/F10 flank melanoma-bearing C57 mice. The biodistribution results of 68 Ga-DOTA-GGNle-CycMSH hex are presented in Table 1 . Ga-DOTA-GGNle-CycMSH hex displayed rapid melanoma uptake. The B16/F10 tumor uptake was 18.63 ± 4.97 and 24.27 ± 3.74% ID/g at 0.5 and 1 hour after injection, respectively.
68
Ga-DOTA-GGNle-CycMSH hex exhibited prolonged tumor retention, with 11.61 ± 2.87% ID/g of tumor uptake at 2 hours after injection. The co-injection of nonradioactive [Nle4, D-Phe7]--melanocytestimulating hormone (NDP-MSH) blocked 92% of the tumor uptake at 1 hour after injection, demonstrating that the tumor uptake was MC1R Ga-DOTA-GGNle-CycMSH hex was rapid, with 85% of the injected dose being washed out of the body via the renal system by 1 hour after injection and 92% of the injected dose cleared by 2 hours after injection. Kidneys have the highest uptake of 68 Ga-DOTA-GGNle-CycMSH hex of normal organs, and renal uptake was 9.22 ± 1.38, 7.78 ± 0.63, and 6.01 ± 0.91% ID/g at 0.5, 1, and 2 hours after injection, respectively. The co-injection of NDP-MSH did not significantly (P > 0.05) reduce the renal uptake, indicating that the renal uptake of 68 Ga-DOTA-GGNle-CycMSH hex was not receptor mediated. The accumulation of 68 Ga-DOTA-GGNle-CycMSH hex in other normal organs was much lower than that in kidneys. High tumor/blood and tumor/normal organ uptake ratios were demonstrated as early as 0.5 hour after injection.
The tumor targeting and biodistribution properties of Ga-DOTAGGNle-CycMSH hex were also determined in M21 human melanomaxenografted nude mice ( Table 2) . As compared to the biodistribution results in B16/F10 melanoma-bearing mice, 68 Ga-DOTA-GGNleCycMSH hex displayed a similar distribution pattern with fast tumor uptake, prolonged tumor retention, and quick urinary clearance in M21 melanoma-xenografted mice. The M21 tumor uptake was 6.05 ± 0.83, 6.07 ± 0.68, and 5.15 ± 0.78 % ID/g at 0.5, 1, and 2 hours after injection, respectively. The tumor uptake was MC1R specific because the co-injection of nonradioactive NDP-MSH blocked 83% of the tumor uptake at 1 hour after injection. M21 tumor uptake was lower than B16/F10 tumor uptake, which is likely attributed to lower MC1R receptor density (34) and to differences in tumor morphology. The M21 tumor is solid unlike the soft and vascularized B16/F10 tumor. Kidneys exhibit the highest uptake of 68 Ga-DOTA-GGNle-CycMSH hex of all normal organs; however, the renal uptake of 68 Ga-DOTAGGNle-CycMSH hex was not MC1R specific because the co-injection of NDP-MSH did not significantly (P > 0.05) reduce renal uptake. Similarly, the accumulation of 68 Ga-DOTA-GGNle-CycMSH hex in other normal organs was much lower than that in the kidneys. Thus, 68 Ga-DOTA-GGNle-CycMSH hex reached high tumor/blood and tumor/ normal organ uptake ratios as early as 0.5 hour after injection.
Melanoma imaging in tumor-bearing mice
Both flank B16/F10 tumors and M21-xenografted tumors could be visualized by PET using 68 Ga-DOTA-GGNle-CycMSH hex as an imaging probe at 0.5, 1, and 2 hours after injection (Fig. 4) . 68 Ga-DOTAGGNle-CycMSH hex displayed the best imaging contrast between tumor and other normal organs at 1 hour after injection for both B16/F10 and M21 flank tumor models, consistent with the biodistribution results. In the B16/F10 pulmonary metastatic melanoma model, 68 Ga-DOTAGGNle-CycMSH hex exhibited substantial uptake in the melanomabearing lung instead of sharp images of metastatic melanoma lesions (Fig. 5 ).
First-in-human melanoma imaging
Similar to preclinical studies, first-in-human imaging of two patients with melanoma demonstrated moderate to strong uptake in metastatic melanoma lesions (Fig. 6 ). Three melanoma metastases in brain, one metastasis in lung, one metastasis in connective tissue, and bulky metastases in small intestine of patient 1 (Fig. 6 , A and C) were easily visualized by PET using 68 Ga-DOTA-GGNle-CycMSH hex . The routine staging per 18 F-FDG PET/CT (Fig. 6 , B and D) was noninferior and therefore also confirmative for true-positive findings regarding the detection of extracerebral lesions. However, because of the high physiological uptake of 18 F-FDG in the brain, additional magnetic resonance imaging (MRI; BM1 and BM2 in Fig. 6 ) was performed to confirm the brain metastases using conventional means. For patient 2, massive melanoma metastases on the left leg and groin lymph node were visualized by PET using either Ga-DOTA-GGNle-CycMSH hex was more heterogeneous, suggesting different MC1R expressions among those metastases.
DISCUSSION
Malignant melanoma is the most lethal form of skin cancer owing to the extreme aggressiveness associated with metastasis. We have been developing radiolabeled -MSH peptides to target MC1Rs for melanoma imaging and therapy because MC1R is expressed on more The nuclei were stained with DAPI (blue). The microscopic images were acquired by confocal laser microscopy at 100× magnification. Scale bar, 20 m. than 80% of melanotic and amelanotic human melanoma metastases (9) . Here, we have demonstrated MC1R targeting and specificity of 68 Ga-DOTA-GGNle-CycMSH hex and Cy5.5-GGNle-CycMSH hex using murine and human melanoma cells, as well as murine melanoma and human melanoma-xenografted tumors. Both B16/F10 and M21 melanoma lesions could be easily imaged by PET using 68
Ga-DOTA-GGNle-CycMSH hex . MC1R expression in B16/F10 and M21 melanoma lesions could be specifically stained by Cy5.5-GGNleCycMSH hex . The promising results on MC1R-specific imaging and staining on both flank melanoma and pulmonary metastatic melanoma lesions suggested the potential of using Cy5.5-GGNle-CycMSH hex for imaging-guided surgery after identifying melanoma lesions using 68 Ga-DOTA-GGNle-CycMSH hex . The combined use of 68 Ga-DOTAGGNle-CycMSH hex and Cy5.5-GGNle-CycMSH hex may potentially improve the surgical outcomes of patients with melanoma via imagingguided surgery.
We and others have been using the B16/F10 pulmonary metastatic melanoma model to evaluate the targeting and imaging properties of radiolabeled -MSH peptides (16, 17, 34) due to the high metastatic nature of the B16/F10 cell line. B16/F10 melanoma cells were injected into mice via tail veins to generate pulmonary melanoma metastases. This inoculation route mimics the development Ga-GGNle-CycMSH hex .
18
F-FDG PET (B, D, and F) studies were performed on the same patients for comparisons. The melanoma metastases in brain (BM1 and BM2) were confirmed by MRI, and the metastasis in connective tissue (CM1) was confirmed by CT. Melanoma metastases are highlighted with arrows on the images. SUV bw , standardized uptake value based on body weight.
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of melanoma metastases through blood circulation, whereas sentinel lymph node is the first organ to develop metastasis in a patient with melanoma. Both B16/F10 flank melanoma lesions and B16/F10 pulmonary metastatic melanoma lesions were positively stained by Cy5.5-GGNle-CycMSH hex , indicating that the metastasis process did not result in a substantial change in the MC1R expression. PET images showed substantial uptake of 68 Ga-DOTA-GGNle-CycMSH hex in B16/F10 pulmonary metastatic melanoma lesions. In our previous work, we demonstrated the success of SPECT imaging of B16/ F10 pulmonary melanoma metastases using 99m Ga-labeled lactam-cyclized -MSH peptides as imaging probes (34, 36) . The difference in imaging quality between SPECT and PET images in this B16/F10 pulmonary metastatic melanoma model was likely attributed to the lower resolution of animal PET as compared to animal SPECT.
After diagnosis of melanoma, it is important to determine whether the melanoma has metastasized to lymph nodes and other distant organs such as liver, lung, and brain. About 60% of patients with metastatic melanoma develop brain metastases during the course of their disease (37) . Patients with brain metastases have much shorter life expectancies than patients without brain metastases. Meanwhile, it is challenging to effectively treat brain metastases without side effects. Here, we could identify the melanoma metastases in brain, as well as in lung, connective tissue, and small intestine of patients by PET using Ga-DOTA-GGNle-CycMSH hex as an MC1R-targeting probe for melanoma imaging. This underscores the need to develop MC1R-targeting therapeutic agents for treating patients with metastatic melanoma.
The PET images of melanoma metastases suggest that MC1R not only is a valid molecular target for melanoma during early development but also is present in advanced stages of melanoma and later generations of daughter metastases. Moreover, the heterogeneous intensity of 68 Ga-DOTA-GGNle-CycMSH hex uptake among melanoma metastases in patient 2 indicates that the MC1R density was different in these metastatic melanoma lesions. From a therapeutic point of view, it is important to note that receptor-targeted radionuclide therapy is much more effective when the receptors are overexpressed in all or at least nearly all tumor lesions. Therefore, it is crucial to identify such patients for potentially successful receptortargeted radionuclide therapy. The PET images of patients with melanoma demonstrate the potential of 68 Ga-DOTA-GGNle-CycMSH hex PET to select patients with sufficient MC1R expression in all metastases before tailoring therapies for these patients toward or against MC1R-targeted radionuclide therapy. We have previously demonstrated the promising melanoma targeting property of 177 Lu-DOTAGGNle-CycMSH hex (32) . 177 Lu is an attractive theranostic radionuclide. When 177 Lu decays, it generates medium-energy (0.497 MeV) -particles for treatment, as well as -rays (113 and 208 keV) for SPECT imaging. The short tissue penetration of -particles makes 177 Lu a suitable radionuclide for treating small tumors and metastases because of its fairly localized radiation emission. Although we have yet to examine the therapeutic efficacy of 177 Lu-DOTA-GGNle-CycMSH hex , the combination of 68 Ga-DOTA-GGNle-CycMSH hex and 177 Lu-DOTA-GGNle-CycMSH hex may potentially offer an attractive approach to receptor-targeted imaging and radionuclide therapy for melanoma.
MC1R is a melanoma-specific molecular target without relevant physiological expression on normal tissues. Despite DOTA-GGNleCycMSH hex exhibiting low nanomolar affinity to MC1R, the relatively low number of MC1R copies per cell could be a potential limiting factor for MC1R-targeted radionuclide therapy. The human imaging doses of 68 Ga-DOTA-GGNle-CycMSH hex were prepared with 7.5 g of DOTA-GGNle-CycMSH hex in this study. However, it is possible that higher amounts of GGNle-CycMSH hex would be needed to deliver more 177 Lu activity to melanoma cells for MC1R-targted radionuclide therapy. Therefore, there is a potential scenario in which increased GGNle-CycMSH hex mass could partially saturate MC1Rs on melanoma cells. More research is needed to determine the threshold amount of GGNle-CycMSH hex without MC1R blocking effect and to achieve high specific activity during radiolabeling or through an additional purification process. Nonspecific renal uptake of 68 Ga-DOTA-GGNle-CycMSH hex could be another potential limiting factor for MC1R-targeted radionuclide therapy. Nonspecific renal uptake of radiolabeled peptide is due to the electrostatic interaction between positively charged peptide molecules and the negatively charged surface of tubule cells as the peptides are filtered in the glomerulus and reabsorbed in the cells of the proximal tubule (38) . Positively charged lysine has been effective in reducing the renal uptake of radiolabeled peptide by shielding such electrostatic interaction (39) (40) (41) , suggesting that co-injection of lysine could be used to further reduce renal uptake if needed.
In conclusion, we demonstrated the MC1R targeting and specificity of 68 Ga-DOTA-GGNle-CycMSH hex and Cy5.5-GGNle-CycMSH hex using murine and human melanoma cells, as well as murine melanoma and human melanoma-xenografted tumors. Both B16/F10 and M21 melanoma lesions could be imaged by PET using Ga-DOTA-GGNle-CycMSH hex as an MC1R-targeting melanoma imaging probe. Furthermore, the successful imaging of melanoma metastases in patients underscored the need to develop MC1R-targeting therapeutic peptides for treating patients with metastatic melanoma.
MATERIALS AND METHODS
Study design
The goal of this work was to assess whether MC1R-targeting 68 Ga-DOTA-GGNle-CycMSH hex could be used to evaluate the possibility of radionuclide therapy on patients with advanced-stage melanoma. First, the MC1R targeting and specificity of 68 Ga-DOTAGGNle-CycMSH hex and Cy5.5-GGNle-CycMSH hex were examined using murine and human melanoma cells, as well as murine melanoma and human melanoma-xenografted tumors. Then, 68 Ga-DOTAGGNle-CycMSH hex was used first in human as an imaging probe to evaluate the possibility of radionuclide therapy on patients with metastatic melanoma who were considered suitable for the evaluation of experimental approaches (in agreement with the Declaration of Helsinki, 37: Unproven Interventions in Clinical Practice) because they had already exhausted all other available treatment options.
Chemicals and reagents
Amino acids and resin were purchased from Advanced ChemTech Inc. and Novabiochem. DOTA-tris-t-butyl ester and Cy5.5 carboxylic acid were purchased from Macrocyclics Inc. and Lumiprobe Corporation, respectively, for peptide synthesis. The Peptide synthesis DOTA-GGNle-CycMSH hex and Cy5.5-GGNle-CycMSH hex were synthesized using standard Fmoc chemistry according to our published procedure (23) 3 DOTA, and Cy5.5 were used for the synthesis. The protecting group of Dde was removed by 2% hydrazine for peptide cyclization. The protecting group of 2-phenylisopropyl was removed, and the protected peptide was cleaved from the resin treating with a mixture of 2.5% of trifluoroacetic acid (TFA) and 5% of triisopropylsilane. After the precipitation with ice-cold ether, each protected peptide was characterized by liquid chromatography-mass spectroscopy (LC-MS). Then, each protected peptide was further cyclized by coupling the carboxylic group from the Asp with the -amino group from the Lys. The cyclization reaction was achieved by an overnight reaction in dimethylformamide using benzotriazole-1-yl-oxy-tris-pyrrolidino-phosphonium-hexafluorophosphate as a coupling agent in the presence of N,N-diisopropylethylamine. After characterization by LC-MS, each cyclized protected peptide was dissolved in H 2 O/CH 3 CN (50:50) and lyophilized. The protecting groups were totally removed by treatment with a mixture of TFA, thioanisole, phenol, water, ethanedithiol, and triisopropylsilane (87.5:2.5:2.5:2.5:2.5:2.5) for 2 hours at room temperature (25°C). Each peptide was precipitated and washed four times with ice-cold ether, purified by RP-HPLC, and characterized by LC-MS. Ga-DOTAGGNle-CycMSH hex was determined by incubation in mouse serum at 37°C for 1 hour and monitored for degradation by RP-HPLC. To determine urine metabolites, HPLC-purified 68 Ga-DOTA-GGNleCycMSH hex (0.74 MBq, 100 l) was injected into a normal C57 mouse through the tail vein. At 2 hours after injection, the mouse was euthanized, and the urine was collected. The radioactive metabolites in the urine were analyzed by HPLC. A 20-min gradient of 18 to 28% CH 3 CN/20 mM HCl was used for the urine analysis. 
Specific binding of
B16/F10 murine melanoma and M21 human melanoma-xenografted melanoma models
All animal studies were conducted in compliance with Institutional Animal Care and Use Committee approval. B16/F10 murine melanoma and M21 human melanoma-xenografted melanoma models were generated for fluorescence staining, biodistribution studies, and imaging studies. For the B16/F10 flank melanoma model, each C57 mouse (4 to 6 weeks, female; Charles River Laboratories) was subcutaneously inoculated with 1 × 10 6 B16/F10 cells on the right flank. Ten days after inoculation, tumor weights reached about 0.2 g. The flank tumor-bearing mice were used for fluorescence staining, biodistribution studies, and imaging studies. For the B16/F10 pulmonary metastatic melanoma model, each C57 mouse was intravenously injected with 2 × 10 5 B16/F10 cells via the tail vein. The mice were used for fluorescence staining 16 days after injection and for imaging studies 21 days after injection. For M21 human melanoma xenografts, each nude mouse (4 to 6 weeks, female; Charles River Laboratories) was subcutaneously inoculated with 5 × 10 6 M21 cells on the right flank. Fourteen days after inoculation, the tumor weights reached about 0.2 g, and these mice were used for fluorescence staining, biodistribution studies, and imaging studies.
Fluorescence staining of melanoma cells and tumor lesions using Cy5.5-GGNle-CycMSH hex B16/F10 and M21 melanoma cells (1 × 10 5 cells per well) were seeded in a four-well Lab-Tek Chamber Glass Slide System from Thermo Fisher Scientific and incubated overnight at 37°C. After 24 hours, the cells were fixed with 4% PFA in PBS and incubated at room temperature for 15 min, washed with PBS three times, treated with 0.5% Triton X-100 at room temperature for 15 min, and washed with PBS three times. The cells were incubated with 1 M Cy5.5-GGNleCycMSH hex with or without 100 M NDP-MSH peptide blockade at room temperature for 1 hour and washed with PBS three times. Then, the cells were stained for nuclei and mounted with DAPI Fluoromount-G mounting medium from SouthernBiotech and stayed in the dark at room temperature for 24 hours. The fluorescent signal was observed and recorded at 100× magnification under an Olympus FV1000 confocal microscope.
Paraffin-embedded B16/F10 and M21 melanoma sections (thickness, 5 m) were incubated with 1 M Cy5.5-GGNle-CycMSH hex with or without 100 M NDP-MSH peptide blockade at room temperature for 1 hour after deparaffinization with xylene. Tissue samples were then washed with PBS three times and stained and mounted with ProLong Diamond antifade mounting reagent with DAPI from Life Technologies. The fluorescent signal was observed and recorded at 100× magnification under an Olympus FV1000 confocal microscope.
Biodistribution of 68
Ga-DOTA-GGNle-CycMSH hex All animal studies were conducted in compliance with Institutional Animal Care and Use Committee approval. The biodistribution properties of 68 Ga-DOTA-GGNle-CycMSH hex were determined on B16/F10 murine melanoma-bearing C57 mice and M21 human melanoma-xenografted nude mice. Each melanoma-bearing mouse was injected with 0.37 MBq of 68 Ga-DOTA-GGNleCycMSH hex via the tail vein. Groups of four mice were euthanized at 0.5, 1, and 2 hours after injection, and tumors and organs of interest were harvested, weighed, and counted. Blood values were taken as 6.5% of the whole-body weight. The specificity of the tumor uptake of 68 Ga-DOTA-GGNle-CycMSH hex was determined by co-injecting 10 g (6.07 nmol) of unlabeled NDP-MSH, which is a linear -MSH peptide analog with subnanomolar MC1R binding affinity.
PET imaging of 68
Ga-DOTA-GGNle-CycMSH hex in melanoma-bearing mice The melanoma imaging property of 68 Ga-DOTA-GGNle-CycMSH hex was determined on B16/F10 flank melanoma-bearing and B16/F10 pulmonary metastatic melanoma-bearing C57 mice and on M21 human melanoma-xenografted nude mice. The melanoma-bearing mice were generated as described above and used for imaging studies. The B16/F10 pulmonary melanoma metastases were generated by injecting B16/F10 cells into the tail vein of each C57 mouse, mimicking the development of metastases via blood circulation. Each melanoma-bearing mouse was injected with 7.4 MBq of 68 Ga-DOTA-GGNle-CycMSH hex via the tail vein. PET imaging studies of live flank melanoma-bearing mice were performed at 0.5, 1, and 2 hours after injection, whereas the imaging study of live pulmonary metastatic melanoma-bearing mice was conducted at 0.5 and 1 hour after injection. Reconstructed PET data were visualized using VivoQuant from Invicro.
First-in-human PET imaging of 68
Ga-DOTA-GGNle-CycMSH hex in patients with metastatic melanoma To assess the eventual possibility of MC1R-targeting radionuclide therapy, 68 Ga-DOTA-GGNle-CycMSH hex PET/CT was offered to two patients with metastatic melanoma. These patients had already failed other available melanoma treatments including chemotherapy (dacarbazine and paclitaxel/carboplatin), immunotherapy (ipilimumab), and BRAF inhibitor (vemurafenib). PD-1 therapy was not available yet at the time of the study. After exhausting all other available treatment options, it was well in line with the updated Declaration of Helsinki (37: Unproven Interventions in Clinical Practice) to consider nonstandard approaches for these individual patients. The patients were informed about the experimental character of the procedure that was offered according to the German Pharmaceutical Act §13(2b) and were given written informed consent. The ethics committee of the University of Heidelberg approved the retrospective evaluation of the obtained data as an observational study.
68 Ga-DOTA-GGNle-CycMSH hex was prepared at pH 3.5 in a 2.5 M NaOAc-buffered solution (pH 9). Briefly, 1 ml of 68 GaCl 3 (600 to 1000 MBq in 0.6 M HCl aqueous solution), 5 l of 1 mM peptide aqueous solution, 10 l of 20% ascorbic acid aqueous solution, and 300 l of 2.5 M NaOAc were added into a reaction vial and incubated at 95°C for 15 min. The pH of the reaction mixture was 3.5. After the incubation, the mixture was purified by solidphase extraction (Varian Bond Elut Plexa from Agilent Technologies) before injection. About 300 to 600 MBq of the purified 68 Ga-DOTAGGNle-CycMSH hex was obtained in 6 ml of 10% ethanol and saline.
The patients underwent imaging on a Siemens Biograph 6 scanner 1 hour after intravenous injection of about 300 MBq of 68 Ga-DOTAGGNle-CycMSH hex . First, a non-contrast-enhanced low-dose CT scan (130 keV, 30 mA, and reconstruction with soft tissue kernel to a slice thickness of 5 mm) was performed and later used for attenuation correction of the related PET scan. Then, three-dimensional emission scans from head to mid-thigh were obtained by eight bed positions (15.5 cm field of view and 3 min of acquisition time, respectively). Images were reconstructed with an ordered subset expectation maximization algorithm correcting for randoms, scatter, and decay using two iterations/16 subsets and Gauss filtered to a transaxial resolution of 5 mm at full width at half maximum.
Statistical analysis
Statistical analysis was performed using the Student's t test for unpaired data. A 95% confidence level was chosen to determine the significant difference between groups in cellular binding of 68 Ga-DOTA-GGNle-CycMSH hex and difference in tumor and renal uptakes between 68 Ga-DOTA-GGNle-CycMSH hex with or without NDP-MSH co-injection. The differences at the 95% confidence level (P < 0.05) were considered significant.
